Treatment of advanced breast cancer in postmenopausal women with aminoglutethimide

ABSTRACT

Aminoglutethimide was used for treatment of 45 postmenopausal patients with disseminated breast cancer. All of them showed progressive disease following prior response to tamoxifen treatment. Eighteen patients received also systemic chemotherapy [CMF regimen] before tamoxifen. The results revealed complete response 2%, partial response 37%, stable disease 15%, and progressive disease 46%. The median duration of objective response was 10 months, and of stable disease 5 months. Previous chemotherapy did not influence the response to aminoglutethimide. The commonest side effects were lethargy and skin rash. The results indicated that aminoglutethimide is an effective, moderately did not influence the commonest side effects were lethargy and skin rash. The results indicated that aminoglutethimide is an effective, moderately well-tolerated, second- line hormonal therapy in postmenopausal patients with advanced breast cancer